☆ 4.6 Letter

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

AMERICAN JOURNAL OF HEMATOLOGY (2022)

The real-world outcomes of multiple myeloma patients treated with daratumumab

Agoston Gyula Szabo et al.

Summary: Real-world outcomes of Danish patients with multiple myeloma treated with daratumumab were worse compared to clinical trial results. Best outcomes were achieved with daratumumab in combination with IMiDs and in early lines of therapy. Patients with high-risk chromosomal abnormalities had worse outcomes, while patients with amp1q had similar outcomes to standard-risk patients.

PLOS ONE (2021)

添加到收藏夹

Article Oncology

Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma in Slovakia

L'ubica Harvanova et al.

Summary: This study evaluated the efficacy and safety of the daratumumab-bortezomib-dexamethasone combination therapy in real-world settings for patients with relapsed/refractory multiple myeloma. The results showed a high overall response rate in patients and equally good progression-free survival outcomes in different risk groups. Adverse events were generally mild and did not lead to permanent drug interruptions.

NEOPLASMA (2021)

添加到收藏夹

Article Hematology

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment

Garbriel Afram et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Ujjawal H. Gandhi et al.

LEUKEMIA (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma

Aleksander Salomon-Perzynski et al.

ADVANCES IN MEDICAL SCIENCES (2019)

添加到收藏夹

Article Hematology

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Szilvia Lovas et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

相关参考文献

The real-world outcomes of multiple myeloma patients treated with daratumumab

Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma in Slovakia

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

导出引文

分享论文